Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05488366 · ClinicalTrials.gov registry record · Early Phase 1

Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

A Early Phase 1 study of Sarcoma,Soft Tissue, sponsored by University of California, Irvine.

Active
Registry status
Early Phase 1
Development phase
9
Enrollment target
1
Study location

NCT05488366: Active Early Phase 1 study of Sarcoma,Soft Tissue, sponsored by University of California, Irvine.

NCT05488366 is a Early Phase 1 study of Sarcoma,Soft Tissue that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 9 participants, below the 77-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05488366, a Early Phase 1 study of Sarcoma,Soft Tissue, is active but no longer recruiting, sponsored by University of California, Irvine.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery.

Primary Outcome

Number of patients completing treatment with at least one cycle of pembrolizumab and completion of RT (Arm A) or completion of RT (Arm B). Up to 6 replacements are allowed (total subjects 6-12)

Conditions Studied

Sarcoma,Soft Tissue

Interventions

  • DRUG Pembrolizumab
  • RADIATION Radiation therapy

Study Locations (1)

California

  • Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2022-08-03
Est. Completion 2026-08
Phase Early Phase 1
University of California, Irvine

368 total trials

What the registry record for NCT05488366 still lists

NCT05488366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 77-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05488366 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05488366 about?

NCT05488366 is a clinical study titled "Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma". This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curati...

What is the current status of trial NCT05488366?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2022-08-03. Estimated completion is 2026-08.

What conditions does trial NCT05488366 study?

This clinical trial studies the following conditions: Sarcoma,Soft Tissue.

What interventions are being tested in trial NCT05488366?

The interventions under investigation include: Pembrolizumab (DRUG), Radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT05488366?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05488366 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma,Soft Tissue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05488366's enrollment target sits among peer trials

9 9th of 12 higher than 3 of 12 other Sarcoma,Soft Tissue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sarcoma,Soft Tissue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05488366, the US trial registry maintained by the National Library of Medicine. NCT05488366 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.